Abstract Negative symptoms remain a main therapeutic challenge in patients with schizophrenia (SZ). Obesity is associated with more severe negative symptoms after the first episode of psychosis. Oxidative stress caused by an impaired antioxidant defense system is involved in the pathophysiology of SZ. Yet, it is unclear regarding the role of obesity and antioxidants in negative symptom improvements in SZ. Therefore, this longitudinal study was designed to assess the impact of obesity on antioxidant defenses and negative symptom improvements in first-episode SZ patients. A total of 241 medication-naive and first-episode patients with SZ were treated with risperidone for 3 months. Outcome measures including symptoms, body weight, and total antioxidant status (TAS) levels were measured at baseline and the end of the third month. We found that after 12 weeks of treatment with risperidone, the body weight increased and clinical symptoms significantly improved. Baseline body mass index (BMI) was negatively correlated with negative symptom improvement after treatment and an increase in TAS was negatively associated with an increase in BMI only in the high BMI group. More importantly, the TAS × BMI interaction at baseline was an independent predictor of negative symptom improvement. Our longitudinal study indicates that the improvement in negative symptoms by risperidone was associated with baseline BMI and TAS levels in patients with SZ. Baseline BMI and TAS may be a predictor for negative improvement in SZ patients after risperidone treatment.
Abstract Objective Cognitive dysfunction is a prevalent and intricate manifestation of schizophrenia (SCZ) that may be associated with distinct clinical factors and the presence of antioxidants, which relationship is unclear. The study aimed to investigate cognitive function and its influencing factors in Chinese patients with SCZ. Methods A group of 133 patients with SCZ and 120 healthy controls (HCs) were recruited. The MATRICS Consensus Cognitive Battery (MCCB) was utilized to evaluate cognitive ability, and the Positive and Negative Syndrome Scale (PANSS) was used to assess clinical symptoms. Levels of plasma superoxide dismutase (SOD), serum albumin (ALB) and uric acid (UA) were assessed. Results Compared with HCs, patients with SCZ exhibited lower cognitive performance as indicated by MCCB scores, including the dimensions of speed of processing, attention/vigilance, working memory, verbal learning, and visual learning. In the SCZ group, total PANSS scores were negatively associated with all MCCB dimensions (all p < 0.05), except for the attention/vigilance score. The PANSS-negative and PANSS-cognitive subscores were negatively associated with speed of processing, verbal learning, and visual learning scores (all p < 0.05). The PANSS-excited subscores showed a negative correlation with working memory and visual learning scores (all p < 0.05). ALB levels significantly decreased, and their UA and SOD levels were notably elevated compared to HCs (all p < 0.05). ALB levels and PANSS-negative factors were correlated with to speed of processing, working memory, and visual learning dimensions. SOD levels were independent contributors to the attention/vigilance dimension. Conclusions The cognitive function was decreased in SCZ. The degree of cognitive impairment was closely related to ALB, SOD levels and negative clinical symptoms.
Abstract The effects of the gut microbiome on the central nervous system and its possible role in mental disorders have received increasing attention. However, our knowledge about the relationship between the gut microbiome and brain structure and function is still very limited. Here, we leveraged 16S rRNA sequencing with structural magnetic resonance imaging (sMRI) and resting-state functional (rs-fMRI) to investigate differences in fecal microbiota between 38 patients with schizophrenia (SZs) and 38 demographically matched normal controls (NCs) and explored whether such differences were associated with brain structure and function. At the genus level, we found that the relative abundance of Ruminococcus and Roseburia was significantly lower, whereas the abundance of Veillonella was increased in SZs compared to NCs. Additionally, the MRI results revealed that several brain regions showed lower gray matter volume (GMV) and regional homogeneity (ReHo), but increased amplitude of low-frequency fluctuation (ALFF) in SZs than in NCs. Statistical analyses were performed to explore the associations between microbial shifts and brain structure and function. Alpha diversity of gut microbiota showed a strong linear relationship with GMV and ReHo. Moreover, we found that lower ReHo indexes in the right STC ( r = -0.35, p = 0.031, FDR corrected p = 0.039), the left cuneus ( r = -0.33, p = 0.044, FDR corrected p = 0.053) and the right MTC ( r = -0.34, p = 0.03, FDR corrected p = 0.052) were negatively correlated with a lower abundance of the genus Roseburia . This study suggests that the potential role of the gut microbiome in schizophrenia (SZ) is related to the alteration of brain structure and function, suggesting a new direction for studying the pathology of SZ.
To analyze the anxiety, depression, and related factors among pregnant women with cervical insufficiency, so as to provide a reference for clinical psychological intervention as an adjuvant therapy.A total of 101 cases in China with cervical insufficiency were included in the observation group by a convenience sampling method, and 114 normal healthy women of childbearing age were selected as the control group. Participants were investigated and observed for anxiety and depression by SAS and SDS, respectively, to analyze the emotional state and influencing factors of the patients with cervical insufficiency. Stratified by the first, second and third trimesters, our study used whether depressive or not and whether anxiety or not as the dichotomous variables. A multivariate Logistic regression was adopted to analyze the influencing factors. Relevant influencing factors were screened out by the forward stepwise method in combination with professional knowledge and the number of variables.There were statistical significant differences in SAS and SDS between observation group and control group and the incidence rate of anxiety and depression was higher in pregnant women with CI. Multivariate Logistic regression demonstrated that history of abnormal pregnancy was the main influencing factor for anxiety and depression in the early and middle gestation phases, and cervical insufficiency was the factor influencing the anxiety in early gestation and both anxiety and depression in the late gestation phase.Cervical insufficiency may have a negative impact on the emotions of pregnant women. Individualized and targeted mental care should be added into clinic work to prevent negative outcomes.
Autoantibodies are present in healthy individuals and altered in chronic diseases. We used repeated samples collected from participants in the NYU Women's Health Study to assess autoantibody reproducibility and repertoire stability over a one-year period using the HuProt array. We included two samples collected one year apart from each of 46 healthy women (92 samples). We also included eight blinded replicate samples to assess laboratory reproducibility. A total of 21,211 IgG and IgM autoantibodies were interrogated. Of those, 86% of IgG (n = 18,303) and 34% of IgM (n = 7,242) autoantibodies showed adequate lab reproducibility (coefficient of variation [CV] < 20%). Intraclass correlation coefficients (ICCs) were estimated to assess temporal reproducibility. A high proportion of both IgG and IgM autoantibodies with CV < 20% (76% and 98%, respectively) showed excellent temporal reproducibility (ICC > 0.8). Temporal reproducibility was lower after using quantile normalization suggesting that batch variability was not an important source of error, and that normalization removed some informative biological information. To our knowledge this study is the largest in terms of sample size and autoantibody numbers to assess autoantibody reproducibility in healthy women. The results suggest that for many autoantibodies a single measurement may be used to rank individuals in studies of autoantibodies as etiologic markers of disease.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)